How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

2,258 results for

adhd Methylphenidate

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

341. The effects of methylphenidate on cognitive function in children with attention-deficit/hyperactivity disorder. (Abstract)

The effects of methylphenidate on cognitive function in children with attention-deficit/hyperactivity disorder. Focusing on behavioral criteria for attention-deficit/hyperactivity disorder (ADHD) diagnosis leads to considerable neuropsychological profile heterogeneity among diagnosed children, as well as variable response to methylphenidate (MPH) treatment. Documenting "cold" executive working memory (EWM) or "hot" self-regulation (SR) neuropsychological impairments could aid (...) in the differential diagnosis of ADHD subtypes and may help to determine the optimal MPH treatment dose. In this study, children with ADHD inattentive type (n = 19), combined type (n = 33), and hyperactive-impulse type (n = 4) underwent randomized controlled MPH trials; neuropsychological, behavioral, and observational data were collected to evaluate the children's responses. Those with moderate or significant baseline EWM/SR impairment showed robust MPH response, whereas response for those with lower baseline

2012 Postgraduate medicine Controlled trial quality: uncertain

342. Melatonin effects in methylphenidate treated children with attention deficit hyperactivity disorder: a randomized double blind clinical trial. Full Text available with Trip Pro

Melatonin effects in methylphenidate treated children with attention deficit hyperactivity disorder: a randomized double blind clinical trial. The aim of this study was to determine melatonin effects on sleep patterns, symptoms of hyperactivity and attention deficiency in children with attention-deficit hyperactivity disorder (ADHD).Children with age range of 7-12 years who had a combined form of ADHD were randomly divided in to 2 groups according to gender blocks. One group took melatonin (3 (...) , did not show any statistically significant differences between the two groups in ADHD scores.Administration of melatonin along with methylphenidate can partially improve symptoms of sleep disturbance. However, it does not seem to reduce attention deficiency and hyperactivity behavior of children with ADHD.

2012 Iranian journal of psychiatry Controlled trial quality: uncertain

343. Remission in Children and Adolescents Diagnosed with Attention-Deficit/Hyperactivity Disorder via an Effective and Tolerable Titration Scheme for Osmotic Release Oral System Methylphenidate. Full Text available with Trip Pro

Remission in Children and Adolescents Diagnosed with Attention-Deficit/Hyperactivity Disorder via an Effective and Tolerable Titration Scheme for Osmotic Release Oral System Methylphenidate. The purpose of this study was to identify the optimal dose of osmotic release oral system methylphenidate (OROS-MPH) using a dosage forced-titration scheme to achieve symptomatic remission in children with attention- deficit/hyperactivity disorder (ADHD). We also evaluated the efficacy and safety (...) of, and patient and parent satisfaction with, the change in therapy from immediate-release methylphenidate (IR-MPH) to OROS-MPH over 10 weeks.We recruited 521 children and adolescents aged 6-18 years with an American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, 4th ed. (DSM-IV) diagnosis of ADHD, who had received IR-MPH treatments (<70 mg/day) for at least 1 month. The treatment, switched from IR-MPH to OROS-MPH according to a conversion scheme, started with a 6-week forced

2012 Journal of Child and Adolescent Psychopharmacology

344. NWP09 in Children With Attention Deficit Hyperactivity Disorder (ADHD)

: February 3, 2016 Last Verified: January 2016 Keywords provided by Pfizer: ADHD methylphenidate extended-release Additional relevant MeSH terms: Layout table for MeSH terms Disease Attention Deficit Disorder with Hyperactivity Hyperkinesis Pathologic Processes Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Mental Disorders Dyskinesias Neurologic Manifestations Nervous System Diseases Signs and Symptoms Methylphenidate Central Nervous System Stimulants Physiological (...) by (Responsible Party): Pfizer Study Details Study Description Go to Brief Summary: The safety and efficacy of a chewable formulation of extended-release methylphenidate will be studied in children with ADHD Condition or disease Intervention/treatment Phase Attention Deficit Hyperactivity Disorder Drug: NWP09 Drug: Placebo Phase 3 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 90 participants Allocation: Randomized Masking: Quadruple

2012 Clinical Trials

345. A Study to Examine the Progression of Attention-Deficit Hyperactivity Disorder (ADHD) Drug Treatment and to Analyze Associated Factors

., Korea: Attention-deficit hyperactivity disorder Developmental disorder Atomoxetine Methylphenidate Psychiatric disorder Additional relevant MeSH terms: Layout table for MeSH terms Disease Attention Deficit Disorder with Hyperactivity Hyperkinesis Pathologic Processes Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Mental Disorders Dyskinesias Neurologic Manifestations Nervous System Diseases Signs and Symptoms Methylphenidate Atomoxetine Hydrochloride Central Nervous (...) : NCT01624649 Recruitment Status : Completed First Posted : June 21, 2012 Last Update Posted : June 9, 2015 Sponsor: Janssen Korea, Ltd., Korea Information provided by (Responsible Party): Janssen Korea, Ltd., Korea Study Details Study Description Go to Brief Summary: The purpose of this observational study is to explore the efficacy of methylphenidate hydrochloride in children and adolescents diagnosed with attention-deficit hyperactivity disorder (ADHD) by Kiddie-scheduled for affective disorders (SADS

2012 Clinical Trials

346. Should Chronic Stimulant Medications be Continued Preoperatively in Patients With Attention Deficit Hyperactivity Disorder(ADHD)

information Responsible Party: Richard Cartabuke, Co-Director of Outpatient Anesthesia Services, Nationwide Children's Hospital ClinicalTrials.gov Identifier: Other Study ID Numbers: IRB12-00721 First Posted: December 4, 2012 Results First Posted: September 26, 2017 Last Update Posted: September 26, 2017 Last Verified: July 2017 Additional relevant MeSH terms: Layout table for MeSH terms Attention Deficit Disorder with Hyperactivity Hyperkinesis Attention Deficit and Disruptive Behavior Disorders (...) Should Chronic Stimulant Medications be Continued Preoperatively in Patients With Attention Deficit Hyperactivity Disorder(ADHD) Should Chronic Stimulant Medications be Continued Preoperatively in Patients With Attention Deficit Hyperactivity Disorder(ADHD) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have

2012 Clinical Trials

347. Efficacy and Safety Study of Combination of Ginkgo Extract and Ginseng Extract in Children With ADHD(Attention Deficit Hyperactivity Disorder)

Efficacy and Safety Study of Combination of Ginkgo Extract and Ginseng Extract in Children With ADHD(Attention Deficit Hyperactivity Disorder) Efficacy and Safety Study of Combination of Ginkgo Extract and Ginseng Extract in Children With ADHD(Attention Deficit Hyperactivity Disorder) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save (...) this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Efficacy and Safety Study of Combination of Ginkgo Extract and Ginseng Extract in Children With ADHD(Attention Deficit Hyperactivity Disorder) (ADHD) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details

2012 Clinical Trials

348. A Simple Behavioral Paradigm to Measure Impulsive Behavior in an Animal Model of Attention Deficit Hyperactivity Disorder (ADHD) of the Spontaneously Hypertensive Rats Full Text available with Trip Pro

A Simple Behavioral Paradigm to Measure Impulsive Behavior in an Animal Model of Attention Deficit Hyperactivity Disorder (ADHD) of the Spontaneously Hypertensive Rats Impulsiveness is an important component of many psychiatric disorders including Attention-deficit/hyperactivity disorder (ADHD). Although the neurobiological basis of ADHD is unresolved, behavioral tests in animal models have become indispensable tools for improving our understanding of this disorder. In the punishment/extinction (...) paradigm, impulsivity is shown by subjects that persevere with responding despite punishment or unrewarded responses. Exploiting this principle, we developed a new behavioral test that would evaluate impulsivity in the most validated animal model of ADHD of the Spontaneously Hypertensive rat (SHR) as compared with the normotensive "control" strain, the Wistar Kyoto rat (WKY). In this paradigm we call the Electro-Foot Shock aversive water Drinking test (EFSDT), water-deprived rats should pass over

2012 Biomolecules & therapeutics

349. Predictors of treatment response in adolescents with comorbid substance use disorder and attention-deficit/hyperactivity disorder. Full Text available with Trip Pro

Predictors of treatment response in adolescents with comorbid substance use disorder and attention-deficit/hyperactivity disorder. Attention-Deficit/Hyperactivity Disorder (ADHD) frequently co-occurs with substance use disorder (SUD) and is associated with poor substance-use treatment outcomes. A trial evaluating osmotic-release oral system methylphenidate (OROS-MPH) for adolescents with ADHD and SUD, concurrently receiving behavioral therapy, revealed inconsistent medication effects on ADHD (...) or SUD. Clinical care for this population would be advanced by knowledge of treatment outcome predictors. Data from the randomized placebo-controlled trial (n = 299) were analyzed. Significant treatment predictors included: 1) Substance use severity, associated with poorer ADHD and SUD outcomes, 2) ADHD severity, associated with better ADHD and SUD outcomes, 3) comorbid conduct disorder, associated with poorer ADHD outcomes, and 4) court-mandated status, associated with better SUD outcomes but poorer

2013 Journal of substance abuse treatment Controlled trial quality: uncertain

350. Dopamine receptor 4 (DRD4) 7-repeat allele predicts methylphenidate dose response in children with attention deficit hyperactivity disorder: a pharmacogenetic study. (Abstract)

Dopamine receptor 4 (DRD4) 7-repeat allele predicts methylphenidate dose response in children with attention deficit hyperactivity disorder: a pharmacogenetic study. Genetic polymorphisms of the dopamine neurotransmitter system have been identified in attention deficit hyperactivity disorder (ADHD). Since stimulant medications act through this system, we sought to determine if the 48 base pair VNTR polymorphism (7- repeat allele) of dopamine receptor gene DRD4 predicts methylphenidate (...) responsiveness.Forty-five children, aged 7-15 years, with ADHD, confirmed by NIMH-DISC-IV, participated in this prospective pharmacogenetic study. Subjects received increasing methylphenidate doses based on serial Conners' Global Index-Parent assessments. Doses to obtain a 10-point improvement and normalization (T-score, 60) were determined. Blood and buccal screening for DRD4 7R was correlated with outcomes.Mean dose for a 10-point CGI-P improvement with DRD4 7R (n=20) was 30 mg (1.00 mg/kg) versus 20 mg (0.49 mg

1 Journal of Child and Adolescent Psychopharmacology

351. Effect of methylphenidate formulation for attention deficit hyperactivity disorder on patterns and outcomes of treatment. (Abstract)

Effect of methylphenidate formulation for attention deficit hyperactivity disorder on patterns and outcomes of treatment. The aim of this study was to assess whether once-daily Concerta extended-release (XR) methylphenidate (MPH) is associated with: (1) better compliance; (2) decreased likelihood of accidents/injuries; and (3) lower health-care resource use over a 1-year period than 3-times-daily immediate-release (IR) MPH in children with attention deficit hyperactivity disorder (ADHD (...) ).Multivariate regression analyses were performed using an administrative database. Inclusion criteria were: (1) an age of 6-12 years at the date of first prescription for XR/IR MPH (index date); (2) patient-level data available for least 6 months before and 12 months after the index date; (3) no ADHD medications in the 6-month prior period; and (4) no XR MPH use by the IR MPH group.IR MPH: n=344, mean age 9.55 years, 76% male; XR MPH: n=1431, mean age 9.78 years, 75% male. XR MPH patients were less likely

1 Journal of Child and Adolescent Psychopharmacology

352. High-dose methylphenidate treatment of attention deficit hyperactivity disorder in a preschooler. (Abstract)

High-dose methylphenidate treatment of attention deficit hyperactivity disorder in a preschooler. Although attention deficit hyperactivity disorder is thought to be present in preschoolers, there are no clear guidelines for dosing stimulant medications in this population. This is a case of a 4-year-old boy who was given 108 mg/day extended-release methylphenidate (OROS) MPH) (6.1 mg/kg/day) by his caregiver with notable behavioral improvement. However, weight loss incurred due to the anorexic (...) side effect of the medication led the clinician to decrease his dose to 72 mg/day OROS MPH (3.7 mg/kg/day). The case highlights that some young children with attention deficit hyperactivity disorder treated with MPH may require higher doses than would be predicted by weight-based dosing. An increased frequency of side effects associated with high doses of MPH necessitates that the clinician balance the positive behavioral response of the medication with adverse side effects in determining ideal

1 Journal of Child and Adolescent Psychopharmacology

353. National Survey of Adherence, Efficacy, and Side Effects of Methylphenidate in Children With Attention-Deficit/Hyperactivity Disorder in Taiwan. (Abstract)

National Survey of Adherence, Efficacy, and Side Effects of Methylphenidate in Children With Attention-Deficit/Hyperactivity Disorder in Taiwan. To identify the determinants of adherence to immediate-release (IR) methylphenidate in children and adolescents with attention-deficit/hyperactivity disorder (ADHD); to examine the impact of adherence on ADHD-related symptoms; and to compare the efficacy, adherence, and side effects of IR methylphenidate and osmotic release oral system (OROS (...) to OROS methylphenidate. The global ADHD severity, parent-child interaction, classroom behavior, academic performance, and side effects of the child subjects were evaluated by investigators. Parents completed the rating scales about the ADHD-related symptoms. The study began in April 2005 and was completed in February 2006.Determinants for poor adherence included older age, later onset of ADHD, family history of ADHD, higher paternal education level, and multi-dose administration. Mental retardation

1 Journal of Clinical Psychiatry

354. Attention Deficit Hyperactivity Disorder (Treatment)

=aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvMjg5MzUwLXRyZWF0bWVudA== processing > Attention Deficit Hyperactivity Disorder (ADHD) Treatment & Management Updated: Dec 26, 2018 Author: Stephen Soreff, MD; Chief Editor: Glen L Xiong, MD Share Email Print Feedback Close Sections Sections Attention Deficit Hyperactivity Disorder (ADHD) Treatment Medical Care The therapeutic approach to ADHD has been shifting. In some cases, environmental restructuring and behavioral therapy alone has been effective. Developments in behavioral parent training (BPT) and behavioral (...) JO. Pharmacotherapy of adult attention deficit/hyperactivity disorder: review of evidence-based practices and future directions. Expert Opin Pharmacother . 2008 May. 9(8):1299-310. . Volkow ND, Swanson JM. Does childhood treatment of ADHD with stimulant medication affect substance abuse in adulthood?. Am J Psychiatry . 2008 May. 165(5):553-5. . Mannuzza S, Klein RG, Truong NL, Moulton JL 3rd, Roizen ER, Howell KH, et al. Age of methylphenidate treatment initiation in children with ADHD and later

2014 eMedicine.com

355. Attention Deficit Hyperactivity Disorder (Follow-up)

. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition . Washington, DC: American Psychiatric Association; 2013. Brown TE. Brown ADD Scales. San Antonio, TX: Psychological Corp; 1996:5-6. Daley D, van der Oord S, Ferrin M, et al, for the European ADHD Guidelines Group. Behavioral interventions in attention-deficit/hyperactivity disorder: a meta-analysis of randomized controlled trials across multiple outcome domains. J Am Acad Child Adolesc Psychiatry . 2014 Aug. 53(8):835-847.e5. . Brauser (...) D. Behavioral interventions effective for ADHD. Medscape Medical News . July 31, 2014. . Spinelli S, Joel S, Nelson TE, Vasa RA, Pekar JJ, Mostofsky SH. Different neural patterns are associated with trials preceding inhibitory errors in children with and without attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry . 2011 Jul. 50(7):705-715.e3. . Ducharme S, Hudziak JJ, Botteron KN, Albaugh MD, Nguyen TV, Karama S, et al. Decreased regional cortical thickness and thinning

2014 eMedicine Pediatrics

356. Attention Deficit Hyperactivity Disorder (Diagnosis)

and tend to remain constant into adulthood. Previous References American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition . Washington, DC: American Psychiatric Association; 2013. Brown TE. Brown ADD Scales. San Antonio, TX: Psychological Corp; 1996:5-6. Daley D, van der Oord S, Ferrin M, et al, for the European ADHD Guidelines Group. Behavioral interventions in attention-deficit/hyperactivity disorder: a meta-analysis of randomized controlled trials across (...) multiple outcome domains. J Am Acad Child Adolesc Psychiatry . 2014 Aug. 53(8):835-847.e5. . Brauser D. Behavioral interventions effective for ADHD. Medscape Medical News . July 31, 2014. . Spinelli S, Joel S, Nelson TE, Vasa RA, Pekar JJ, Mostofsky SH. Different neural patterns are associated with trials preceding inhibitory errors in children with and without attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry . 2011 Jul. 50(7):705-715.e3. . Ducharme S, Hudziak JJ, Botteron

2014 eMedicine Pediatrics

357. Attention Deficit Hyperactivity Disorder (Overview)

Scans Reveal Action of Methylphenidate in Brain. Psychiatric News . Sept 21, 2001. 36, 18: Kooistra L, van der Meere JJ, Edwards JD, Kaplan BJ, Crawford S, Goodyear BG. Preliminary fMRI findings on the effects of event rate in adults with ADHD. J Neural Transm . 2010 Feb 16. . Cherkasova MV, Hechtman L. Neuroimaging in attention-deficit hyperactivity disorder: beyond the frontostriatal circuitry. Can J Psychiatry . 2009 Oct. 54(10):651-64. . Yang P, Wu MT, Dung SS, Ko CW. Short-TE proton magnetic (...) in adulthood?. Am J Psychiatry . 2008 May. 165(5):553-5. . Mannuzza S, Klein RG, Truong NL, Moulton JL 3rd, Roizen ER, Howell KH, et al. Age of methylphenidate treatment initiation in children with ADHD and later substance abuse: prospective follow-up into adulthood. Am J Psychiatry . 2008 May. 165(5):604-9. . Semrud-Clikeman M, Pliszka S, Liotti M. Executive functioning in children with attention-deficit/hyperactivity disorder: Combined type with and without a stimulant medication history. Neuropsychology

2014 eMedicine.com

358. Attention Deficit Hyperactivity Disorder (Follow-up)

Disorder? Evidence From a Four-Decade Longitudinal Cohort Study. Am J Psychiatry . 2015 May 22. appiajp201514101266. . Rosack J. PET Scans Reveal Action of Methylphenidate in Brain. Psychiatric News . Sept 21, 2001. 36, 18: Kooistra L, van der Meere JJ, Edwards JD, Kaplan BJ, Crawford S, Goodyear BG. Preliminary fMRI findings on the effects of event rate in adults with ADHD. J Neural Transm . 2010 Feb 16. . Cherkasova MV, Hechtman L. Neuroimaging in attention-deficit hyperactivity disorder: beyond (...) of ADHD: is it an American condition?. World Psychiatry . 2003 Jun. 2(2):104-113. . Kaplan HI, Sadock BJ, Grebb JA. Kaplan and Sadock's Synposis of Psychiatry . 7th ed. Baltimore, Md: Williams & Wilkins; 1994. 1063-8. Rugino TA, Samsock TC. Modafinil in children with attention-deficit hyperactivity disorder. Pediatr Neurol . 2003 Aug. 29(2):136-42. . Shillington AM, Reed MB, Lange JE, Clapp JD, Henry S. College undergraduate Ritalin abusers in Southwestern California: Protective and Risk Factors. J

2014 eMedicine.com

359. Attention Deficit Hyperactivity Disorder (Diagnosis)

Scans Reveal Action of Methylphenidate in Brain. Psychiatric News . Sept 21, 2001. 36, 18: Kooistra L, van der Meere JJ, Edwards JD, Kaplan BJ, Crawford S, Goodyear BG. Preliminary fMRI findings on the effects of event rate in adults with ADHD. J Neural Transm . 2010 Feb 16. . Cherkasova MV, Hechtman L. Neuroimaging in attention-deficit hyperactivity disorder: beyond the frontostriatal circuitry. Can J Psychiatry . 2009 Oct. 54(10):651-64. . Yang P, Wu MT, Dung SS, Ko CW. Short-TE proton magnetic (...) in adulthood?. Am J Psychiatry . 2008 May. 165(5):553-5. . Mannuzza S, Klein RG, Truong NL, Moulton JL 3rd, Roizen ER, Howell KH, et al. Age of methylphenidate treatment initiation in children with ADHD and later substance abuse: prospective follow-up into adulthood. Am J Psychiatry . 2008 May. 165(5):604-9. . Semrud-Clikeman M, Pliszka S, Liotti M. Executive functioning in children with attention-deficit/hyperactivity disorder: Combined type with and without a stimulant medication history. Neuropsychology

2014 eMedicine.com

360. Attention Deficit Hyperactivity Disorder (Overview)

and tend to remain constant into adulthood. Previous References American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition . Washington, DC: American Psychiatric Association; 2013. Brown TE. Brown ADD Scales. San Antonio, TX: Psychological Corp; 1996:5-6. Daley D, van der Oord S, Ferrin M, et al, for the European ADHD Guidelines Group. Behavioral interventions in attention-deficit/hyperactivity disorder: a meta-analysis of randomized controlled trials across (...) multiple outcome domains. J Am Acad Child Adolesc Psychiatry . 2014 Aug. 53(8):835-847.e5. . Brauser D. Behavioral interventions effective for ADHD. Medscape Medical News . July 31, 2014. . Spinelli S, Joel S, Nelson TE, Vasa RA, Pekar JJ, Mostofsky SH. Different neural patterns are associated with trials preceding inhibitory errors in children with and without attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry . 2011 Jul. 50(7):705-715.e3. . Ducharme S, Hudziak JJ, Botteron

2014 eMedicine Pediatrics

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>